ArticleToxics2026
Hormonal Activity of 3D Bioprinting Materials Using the E-Screen and PALM Bioassays.
Article in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Three-dimensional (3D) printing and bioprinting technologies are increasingly used in tissue engineering and in the development of personalized medical devices with tailored biological and mechanical properties. Despite their advantages, these technologies may involve exposure to chemical compounds with uncertain biological effects, including potential endocrine-disrupting activity. This study aims to evaluate the hormonal activity and cytotoxicity of various materials commonly used for 3D printing technologies, including thermoplastics and synthetic materials (PLA, ABS, PCL, b-TPUe, PVA, PEGDA), and biomaterials (collagen, alginate, hyaluronic acid, agarose, silk fibroin, GelMA, HAMA). Hormonal activity was evaluated using the E-screen assay for estrogenic and anti-estrogenic activity, and the PALM assay for androgenic and anti-androgenic activity. Cytotoxic effects are evaluated by assessing cellular metabolic viability using the MTT assay. No detectable estrogenic, anti-estrogenic, androgenic, or anti-androgenic activity, nor any signs of cytotoxicity, were observed within the experimental conditions analysed. This study represents the first analysis of some specific endocrine-related endpoints of a wide range of 3D printing and bioprinting materials, and should not be interpreted as definitive proof of the complete absence of endocrine activity. Further studies addressing additional toxicological parameters and long-term assessments are required to comprehensively characterize their safety and suitability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.